Metastatic breast cancer with double heterozygosity for the < em > BRCA1 < /em > and < em > BRCA2 < /em > genes responding to olaparib: A case report
In conclusion, the present study reported a female patient with double heterozygosity of BRCA1 and BRCA2 who benefited from olaparib monotherapy. Thus, olaparib may be a suitable treatment for such patients.PMID:38646498 | PMC:PMC11027096 | DOI:10.3892/ol.2024.14387 (Source: Oncology Letters)
Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Bin Shao Lijun Di Source Type: research
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
CONCLUSION: RAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.TRIAL REGISTRATION: INPLASY registration number INPLASY2022120023.PMID:38619719 | DOI:10.1007/s12325-024-02838-5 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Xiaotian Zhang Li Zhou Chan Zhou Lin Shen Source Type: research
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
CONCLUSION: RAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.TRIAL REGISTRATION: INPLASY registration number INPLASY2022120023.PMID:38619719 | DOI:10.1007/s12325-024-02838-5 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Xiaotian Zhang Li Zhou Chan Zhou Lin Shen Source Type: research
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
ConclusionRAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.Trial RegistrationINPLASY registration number INPLASY2022120023. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
CONCLUSIONS: All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.PMID:38594880 | DOI:10.1093/jjco/hyae044 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Naoyuki Nogami Toshio Kubo Akihiro Bessho Makoto Sakugawa Satoshi Ikeo Toshihide Yokoyama Nobuhiko Seki Ryosuke Ochiai Nobukazu Fujimoto Shuji Murakami Kyoichi Kaira Toshiyuki Harada Daizo Kishino Yuichi Takiguchi Tsuneo Shimokawa Katsuyuki Kiura Natsumi Source Type: research
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
CONCLUSIONS: All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.PMID:38594880 | DOI:10.1093/jjco/hyae044 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Naoyuki Nogami Toshio Kubo Akihiro Bessho Makoto Sakugawa Satoshi Ikeo Toshihide Yokoyama Nobuhiko Seki Ryosuke Ochiai Nobukazu Fujimoto Shuji Murakami Kyoichi Kaira Toshiyuki Harada Daizo Kishino Yuichi Takiguchi Tsuneo Shimokawa Katsuyuki Kiura Natsumi Source Type: research
Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer
This study aimed to compare the efficacy of pyrotinib, trastuzumab combined with chemotherapy with different lines therapy in human epidermal growth factor receptor 2- (HER2-) positive advanced breast cancer (ABC) and analyze the factors affecting the prognosis. A total of 84 patients with median age of 49 year-old. The mPFS of patients receiving first-line pyrotinib plus trastuzumab and chemotherapy was the longest (11 months) compared with second- and third line patients (p = 0.106). The objective response rate (ORR) and disease control rate (DCR) of the total population were 33.3% and 82.1% respectively. Subgroup analys...
Source: Journal of Chemotherapy - April 1, 2024 Category: Cancer & Oncology Authors: Yangqingqing Zhou Hui Wang Jiao Yang Fan Wang Danfeng Dong Xiaoai Zhao Le Wang Ruiyuan He Zhiping Ruan Jin Yang Source Type: research
Esophageal squamous cell carcinoma transformed into neuroendocrine carcinoma after neoadjuvant immunochemotherapy: A case report
In conclusion, histological transformation to ENEC is a potential mechanism of acquired resistance to ICIs in ESCC. Prospective larger studies are warranted to further characterize ESCC-to-NEC transformation on use of ICIs.PMID:38476207 | PMC:PMC10928968 | DOI:10.3892/ol.2024.14317 (Source: Oncology Letters)
Source: Oncology Letters - March 13, 2024 Category: Cancer & Oncology Authors: Gaojie Xin Naicheng Song Ke Jiang Source Type: research
